Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine, VisAcT, 18F F ARAG + [4] |
Target |
Mechanism DCK inhibitors(Deoxycytidine kinase inhibitors), DGUOK inhibitors(deoxyguanosine kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H12FN5O4 |
InChIKeyUXUZARPLRQRNNX-YXAALHNKSA-N |
CAS Registry1268848-88-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Phase 2 | US | 28 Sep 2021 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 15 Apr 2021 | |
Melanoma | Phase 2 | US | - | 24 Sep 2020 |
Non-Small Cell Lung Cancer | Phase 2 | - | 26 Nov 2017 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 2 | US | 07 Mar 2017 | |
Bladder Cancer | Phase 2 | US | 07 Mar 2017 | |
Esophageal Carcinoma | Phase 1 | US | - | 29 Nov 2024 |
COVID-19 | Phase 1 | US | 15 Apr 2021 | |
HIV Infections | Phase 1 | US | 21 Sep 2018 | |
Graft vs Host Disease | Phase 1 | US | 15 May 2018 |
Phase 2 | 4 | Positron Emission Tomography+Fluorine F 18 Ara-G | dujfsovzup(yyccjitjic) = xpfuotukjb lxdeauvrun (ywoyrmzcsc, bscbdpxvzq - mqewrvsfsl) View more | - | 21 Jan 2020 |